Last reviewed · How we verify

Abiraterone acetate standard dose — Competitive Intelligence Brief

Abiraterone acetate standard dose (Abiraterone acetate standard dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CYP17 inhibitor. Area: Oncology.

phase 2 CYP17 inhibitor CYP17 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Abiraterone acetate standard dose (Abiraterone acetate standard dose) — Assistance Publique - Hôpitaux de Paris. Inhibits CYP17, an enzyme involved in the production of androgens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Abiraterone acetate standard dose TARGET Abiraterone acetate standard dose Assistance Publique - Hôpitaux de Paris phase 2 CYP17 inhibitor CYP17
NIRAPARIB NIRAPARIB marketed PARP-1, PARP-2, CYP17 2017-01-01
Abiraterone Acetate abiraterone Pfizer marketed Androgen biosynthesis inhibitor CYP17 2011-01-01
Abiraterone with Prednisone or Enzalutamide Abiraterone with Prednisone or Enzalutamide Curium US LLC phase 3 CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone)
SoluMatrix™ Abiraterone Acetate SoluMatrix™ Abiraterone Acetate GU Research Network, LLC phase 3 CYP17 inhibitor CYP17
Fuzuloparib , Abiraterone acetate and Prednisone Fuzuloparib , Abiraterone acetate and Prednisone Jiangsu HengRui Medicine Co., Ltd. phase 3 PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone) PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone)
Abiraterone + Prednisolone/Prednisone Abiraterone + Prednisolone/Prednisone AstraZeneca phase 3 CYP17A1 inhibitor (androgen synthesis inhibitor) + glucocorticoid CYP17A1 (17α-hydroxylase/17,20-lyase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CYP17 inhibitor class)

  1. Cougar Biotechnology, Inc. · 2 drugs in this class
  2. Janssen Research & Development, LLC · 2 drugs in this class
  3. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  5. GU Research Network, LLC · 1 drug in this class
  6. Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abiraterone acetate standard dose — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone-acetate-standard-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: